EUVIMEDEUVIMED entdecken
Crossref

Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013–2024): a pharmacovigilance study

Marya Ahsan

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-03 · 399 (5) · 6939-6958

DOI: 10.1007/s00210-025-04841-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 01.12.2025. Verfasst von Marya Ahsan. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. maahsan@imamu.edu.sa. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To analyze reporting trend, character and factors associated with serious adverse events (SAEs) following sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy in the FAERS database and detect pharmacovigilance signals. Standardized data were subjected to descriptive analysis. Odds ratio (OR) with 95% confidence interval (CI) was calculated to identify associated factors. Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and 95% lower credibility interval of Information Component (IC025) were used to detect signals. 28709 reports (45%) were identified as SAE reports with SGLT2i as primary suspect. Hospitalization (66.86%) and death (20.21%) were major contributors. Dapagliflozin and empagliflozin accounted for more than 70% SAE reports, followed by canagliflozin (26.63%). Male gender (OR = 1.4, 95% CI = 1.35-1.45), age more than 65 years (OR = 1.72, 95% CI = 1.66-1.79) and canagliflozin (OR = 2.05, 95% CI = 1.94-2.16) were identified as factors associated with SAE. Dapagliflozin was associated with death (adjusted OR = 5.22, 95% CI = 4.77-5.72), while canagliflozin had the highest association with hospitalization (adjusted OR = 2.65, 95% CI = 2.52-2.79). 435 signals were detected of which 112 were strong signals (IC025 > 4). Fournier's gangrene (NPS = 1152, IC = 6.84), acute osteomyelitis (175, 6.59), limb amputation (129, 6.79), metatarsal excision (81, 6.79) and euglycemic diabetic ketoacidosis (1485, 6.75) were top signals. Cellulitis, acute pancreatitis and necrotizing pancreatitis were unexpected signals with SGLT2i. Conclusion: SAE reports contributed to a large proportion of reports with SGLT2i in the FAERS database. SAE profile of individual SGLT2i varied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAdverse Drug Reaction Reporting SystemsHumansPharmacovigilanceMaleFemaleDatabases, FactualMiddle AgedAgedAdultCanagliflozinYoung AdultDiabetes Mellitus, Type 2Aged, 80 and overGlucosidesHospitalizationBenzhydryl Compounds

Stichwörter der Autor:innen

AmputationDiabetic ketoacidosisDisproportionality analysisFournier’s gangreneOsteomyelitisSerious outcomes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozinGlucosidesdapagliflozinBenzhydryl Compounds

Autor:innen und Institutionen

  • Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. maahsan@imamu.edu.sa.

Zitieren

APA

Ahsan, M. (2026). Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013–2024): a pharmacovigilance study. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(5), 6939-6958. https://doi.org/10.1007/s00210-025-04841-1

Vancouver

Ahsan M. Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013–2024): a pharmacovigilance study. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(5):6939-6958. doi:10.1007/s00210-025-04841-1

BibTeX
@article{Ahsan2026,
  author = {Ahsan, Marya},
  title = {Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013–2024): a pharmacovigilance study},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  volume = {399},
  number = {5},
  pages = {6939--6958},
  doi = {10.1007/s00210-025-04841-1}
}
Kostenlos starten →